RxDoctor Payments Data

Janet Beebe

Nurse Practitioner · Bowie, MDNPI 1710981709

Payments from drug & device makers

$4,750in general payments, 2019–2025

Across 206 payments — averaging $23.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Collegium Pharmaceutical, Inc.$899
  • Indivior Inc.$339
  • Braeburn Inc.$230
  • Alkermes, Inc.$215
  • Lundbeck LLC$190
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$4,736100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,750 in reported general payments places this provider in the 95th percentile of 1,562 nurse practitioner providers in Maryland.

See all nurse practitioner providers in Maryland

Medicare billing

Part B allowed, 2024
$45,699
Medicare patients
114
Services billed
389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate56$27,380
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl114$24,890
VraylarCariprazine Hcl16$20,807
OzempicSemaglutide15$13,929
UbrelvyUbrogepant14$12,807
Oxymorphone Hcl ErOxymorphone Hcl26$9,945
EliquisApixaban16$9,516
ZubsolvBuprenorphine Hcl/Naloxone Hcl11$7,459
SuboxoneBuprenorphine Hcl/Naloxone Hcl16$6,623
Oxycodone Hcl174$4,897
Lidocaine24$3,902
Diclofenac Sodium22$2,675
Morphine Sulfate ErMorphine Sulfate56$1,958
Tizanidine Hcl48$1,634
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen56$1,418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Ubrelvy, Synthroid$1,271$34,75842 claims
Collegium Pharmaceutical, Inc.Xtampza Er$899$27,38056 claims
PfizerEliquis$175$9,51616 claims
Orexo US, Inc.Zubsolv$141$7,45911 claims
Indivior Inc.Suboxone$339$6,62316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,562 nurse practitioner providers in Maryland.

Other nurse practitioner in Bowie

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →